Cellectis Inc.

Good morning, and everyone, welcome to CELTI's second quarter 2023 earnings call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. Please be aware that today's conference call is being recorded. I'd now like to introduce the first speaker, Arthur Strill, Chief Business Officer. You may begin.

Good morning, and welcome everyone to Selective Second Quarter 2023 Corporate Update and Financial Results Conference Call. Joining me on the call today with prepared remarks are Dr. André Choulika, our Chief Executive Officer, Dr. Bing Wang, our Chief Financial Officer, and Dr. Mark Fettini, our Chief Medical Officer. Yesterday evening, Selectus issued a press release reporting a corporate and business update for the second quarter 2023, and its non-audited financial results for the six-month period ended June 30th, 2023. As disclosed in our press release published yesterday, the report including our non-audited financial statements for Q2 will be released in the coming days. As a reminder, we'll make statements regarding Selectus financial outlook, including the sufficiency of cash to fund operation, in addition to its manufacturing, regulatory and product development status and plans, and product development of its licensed partners. These forward statements, which are based on our management's current expectations and assumptions, and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20F filed with the Security Exchange Commission, SEC, and the financial reports, including the management report, for the year ended on December 31st, 2022, and subsequent filing selected makes with the SEC from time to time. I would now like to turn the call over to Andre.

Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. The second 2023 quarter was marked by strong execution. Our last clinical data presented for UCAR T22 at the European Hematology Association annual meeting are encouraging for patients with relapsed or refractory B-cell acute lymphoblastic leukemia who have failed multiple lines of treatment options, including chemoimmunotherapy, CD19-directed CAR-T cell therapy, and allogeneic stem cell transplant. We're looking forward to releasing our new data later this year on UCAR-T22 manufactured in-house. Blechtis also presented an encore of the clinical data of the AMELY-01 clinical trial evaluating UCAR-T123 at the American Society of Gene and Cell Therapy annual meeting. These preliminary data support the continued administration of UCAR T123 after fludarabine, cyclophosphamide, and alamthuzumab lymphodepletion in patients with relapsed or refractory acute myeloid leukemia. In addition, this quarter, The LECTUS innovation team was proud to present strong preclinical data on gene editing process to develop a bonafide HBB gene correction of sickle mutation. In addition to that, we have presented a comprehensive analysis to better design efficient TAO-based editor at the International Society of Cell and Gene Therapy annual meeting. These achievements showcase more the power of gene editing platform, both as tailings for therapeutic gene editing and that we are continuing to deliver constant breakthrough innovation to treat diseases with unmet medical needs. Blectus announced that during this annual shareholder meeting, Dr. Cecile Chartier has been appointed as a director of the company's board of director. At the end of this meeting, The terms of the office of Mr. Opno and Mrs. Fadig ended. I'm very pleased to welcome Dr. Chartier to select this board. Her extensive experience in the development of next generation cell and gene therapies, coupled with her deep knowledge of U.S. biotechnology industry, will be a huge asset to Selectus. We look forward to her contribution and insights as we continue advancing the development of our product candidates. In 2023, we made substantial progress with our pipeline. Despite an unprecedented challenging market environment for the cell and gene therapies company, Selectis remains deeply focused on its core clinical trial, Bally01 Evaluating UCAR T22, Natalie 01 evaluating UCAR T20 by 22, and Emily 01 evaluating UCAR T123, and on its mission to develop innovative cancer therapy product candidate. With that, I would like to turn the call over to Dr. Frattini, our chief medical officer, who will give an overview of these clinical trials. Mark, please go ahead.